Hepatitis C Medicines
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Status | complete |
|---|---|
| Category (CPV) | 33600000 |
| Region | Scotland |
| Procedure | limited |
| OCID | ocds-h6vhtk-0313c0 |
Awards (4)
This procurement was awarded to 4 suppliers. Values shown are per-award; the notice total is ·.
| Supplier | Value | Date | Status |
|---|---|---|---|
| AbbVie Ltd shared | · | · | active |
| Gilead Sciences Ltd shared | · | · | · |
| Merck Sharp & Dohme UK Ltd shared | · | · | · |
| MSD shared | · | · | · |
description
The framework agreement is awarded for the supply of medicines used to treat Hepatitis C to NHS Scotland.
documents
- Hepatitis C Medicines , awardNotice
- Hepatitis C Medicines , awardNotice
Documents are linked, not mirrored. They are served by the publishing authority and may require registration.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 7 Feb 2022 | Voluntary ex-ante transparency (F15) | Earlier regulations | 003365-2022 |
more from NHS National Services Scotland
- NSS01523 Cycle to Work · £366,000 · 18 Mar 2026
- SNBTS TCAT-Dev Flow Cytometer · £138,084 · 9 Feb 2026
- Direct Meal Service · £15,856,899 · 7 Oct 2025
- Purchase of Pacemakers, ICD's & CRT's · £43,750,000 · 18 Dec 2024
- NP37324 Bulk Medical Liquid Oxygen and Associated Equipment and Services · £19,370,000 · 11 Oct 2024
- NP610524 Out of Hours (Urgent and Unscheduled Care) System · £155,000 · 8 Aug 2024
- Oesophageal Cell Collection Device (OCCD) and Pathology Service · £664,000 · 27 May 2024
- NP67524 Neurosurgery · £5,000,000 · 24 May 2024
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Public Contracts Scotland. Contact details for named individuals are not reproduced on this site.